Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Britain Courts Anthropic Amid US Defense Department Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
JERSEY CITY, N.J., Aug. 31, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences:
- The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m. ET.
- The 23rd Annual NewsMakers in the Biotech Industry Investment Conference at the Millennium Broadway in New York on Friday, September 9, 2016 at 9:30 a.m. ET.
- The Aegis Growth Conference at the Wynn Las Vegas on Thursday, September 22, 2016 at 9:00 a.m. PT.
Live webcasts of the presentations will be available on the investors section of the Company's website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentations.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 [email protected]
